A personalized cancer shot built from a patient’s own tumor just cut the risk of deadly melanoma coming back by nearly half in a major late-stage trial.
Quick Take
- Merck and Moderna’s mRNA-based melanoma therapy, given with the drug Keytruda, hit its main goals in a Phase 3 trial called INTerpath-001.
- Earlier data from a smaller trial showed a 49% drop in the risk of recurrence or death after five years of follow-up.
- The treatment is custom-built for each patient using their own tumor’s genetic mutations.
- Moderna and Merck stock both jumped sharply after the companies shared the results.
What The Phase 3 Trial Actually Found
Merck and Moderna announced that their Phase 3 INTerpath-001 trial met both key goals. The therapy, called intismeran autogene (also known as V940 or mRNA-4157), slowed the return of melanoma and stopped it from spreading to other body parts. This happened when the shot was paired with Keytruda, Merck’s widely used immune therapy drug, in patients with high-risk melanoma.
This trial followed patients whose melanoma tumors had already been surgically removed. Doctors call this an adjuvant treatment, meaning it’s given after surgery to stop cancer from coming back. The combination beat Keytruda alone on both recurrence-free survival and distant metastasis-free survival, the two measures regulators care about most for approval.
How The Earlier Data Built The Case
Before the Phase 3 win, an earlier mid-stage study called KEYNOTE-942 laid the groundwork. In December 2022, Merck and Moderna said the combo cut the risk of recurrence or death by 44% compared to Keytruda alone in stage III and IV melanoma patients. That first signal was strong enough to justify moving into a bigger, later-stage trial.
Follow-up data kept improving as time passed. At the five-year mark, the companies reported a 49% reduction in the risk of recurrence or death, and a 59% drop in the risk of the cancer spreading to distant organs, compared to Keytruda alone. Nearly 69% of combination-therapy patients stayed cancer-free after five years, versus about 49% on Keytruda alone, according to National Public Radio’s report on the data.
Why This Vaccine Works Differently Than A Flu Shot
This is not a preventive vaccine like a flu shot. It’s built after the fact, for one specific patient. Doctors sequence the DNA from a patient’s tumor, find the unique mutations driving that cancer, and use computer software to design an mRNA shot that trains the immune system to attack those exact mutated proteins, called neoantigens.
That personalized approach is also why the process is complicated and expensive. Each dose requires tumor sequencing, custom mRNA design, and manufacturing built around one person’s cancer, not a mass-produced batch. Researchers note the field has moved from early feasibility studies to actual clinical benefit, but scaling up production remains a real challenge going forward.
Market Reaction And What Comes Next
Wall Street reacted fast. Moderna’s stock jumped sharply the day the Phase 3 results came out, and Merck shares moved higher too, reflecting investor belief that a personalized cancer vaccine could become a real product, not just a research headline. Moderna CEO Stรฉphane Bancel called the five-year data a breakthrough moment for the company’s cancer vaccine program.
๐งฌ **๐ ๐ข๐๐๐ฅ๐ก๐ ๐๐ก๐ ๐ ๐๐ฅ๐๐'๐ฆ ๐ ๐ฅ๐ก๐ ๐ ๐๐๐๐ก๐ข๐ ๐ ๐ฉ๐๐๐๐๐ก๐ ๐๐๐๐๐ฅ๐ฆ ๐ฃ๐๐๐ฆ๐ ๐ฏ, ๐๐ฃ๐ฃ๐ฅ๐ข๐ฉ๐๐ ๐ฃ๐ข๐ฆ๐ฆ๐๐๐๐ ๐๐ฌ ๐ฎ๐ฌ๐ฎ๐ณ
๐งช Interim results from a Phase 3 trial of intismeran, a personalized mRNA cancer vaccine, met both primary and secondaryโฆ pic.twitter.com/EwcAaCv7iS
— Vortex Report (@VortexReportX) August 20, 2026
The next step is regulatory review, where the Food and Drug Administration will decide whether the Phase 3 data supports approval for high-risk melanoma patients. Melanoma is one of the deadliest skin cancers once it spreads, so a therapy that meaningfully delays recurrence and distant spread would matter for thousands of patients each year. Bigger studies in other cancer types are also underway, testing whether this personalized mRNA approach works beyond skin cancer alone.
Sources:
insiderpaper.com, merck.com, cnbc.com, pubs.acs.org
